Hepatitis C virus and the risk to the healthcare worker

P Greyling MBChB(Pret), MMed(Orth)(Pret), FCS(Orth)SA
Consultant, Orthopaedic Surgery, Steve Biko Academic Hospital
Prof TLB le Roux MBChB(Pret), MMed(Orth)(Pret), FCS(Orth)SA
Head of Department Orthopaedic Surgery, 1 Military Hospital, Department of Orthopaedic Surgery, Steve Biko Academic Hospital, University of Pretoria, Faculty of Health Sciences
L Botha MBChB(Pret)
Orthopaedic Registrar, 1 Military Hospital

Correspondence:
Dr P Greyling
Department of Orthopaedic Surgery
Steve Biko Academic Hospital
Pretoria
South Africa
Tel: 012 354 2851
Email: pgrey@live.com

Abstract
The risk of hepatitis C virus (HCV) transmission is six times higher per needle-stick exposure than is the risk of HIV infection (1.8% vs 0.3%). The prevalence of HCV in South Africa is not known but estimated to be between 0.1 and 0.7%. Genotype 5 is predominantly found in South Africa. Currently there is no protocol in place for HCV exposure. The treatment cost of HCV is expensive. Currently none of the insurance companies covers post-HCV exposure.

Key words: hepatitis C virus, transmission risk, post-exposure protocol

Introduction
South African surgeons need to familiarise themselves with the risk of acquiring hepatitis C virus (HCV) via sharps injury (SI). Any of the 60 blood-borne pathogens (BBP) may be transferred by SI, the three foremost being the human immunodeficiency virus (HIV), hepatitis B virus (HBV) and HCV. In South Africa (SA) there is little prevalence of HBV (5–7%) and the greatest risk is from HIV (17.9%) for which there are documented protocols and insurance cover. A Canadian surgeon recently acquired HCV from an SI and was banned from practice for 6 months – testimony of the importance of HCV as a disease risk to surgeons.

This paper outlines the prevalence of HCV in SA, the incubation and outcomes of HCV infection, the tests and medications available, and the protective strategies available to minimise HCV exposure.

Epidemiology
Hepatitis C virus was discovered in 1989; it is a small 50 nm, single-stranded RNA virus that belongs to the Flaviviridae family. There are six major HCV genotypes, with five more having recently been added (7–11), and more than 50 subtypes have been described. Genotype 5 is predominantly found in SA (40% of all HCV genotypes). The virus is able to mutate which results in changes that allow the virus to replicate and escape immune surveillance. The result is that HCV infecting humans are remarkably heterogeneous, with only a 70% similarity among all known isolates.
Prevalence and risk of HCV transmission
(Figures 1–3)

The prevalence of HCV in SA is not known but estimated to be between 0.1 and 0.7% (WHO up to 10% in some areas). Three per cent of the world’s population is estimated to be infected with HCV (130–170 million people). The World Health Organisation (WHO) has calculated that unsafe medical devices account for 2.3 million new HCV infections per year and 200 000 premature HCV-related deaths. The risk of HCV transmission is six times higher per needle-stick exposure than is the risk of HIV infection (1.8% vs 0.3%).

Burden of disease

HCV is responsible for more than 350 000 deaths annually. Unsafe injections in healthcare settings result in 2 million new HCV infections yearly. Up to 30% of people infected with HIV are also infected with HCV. Unless the disease is contained, the death rate from HCV will rise to a level greater than that of AIDS.

The cost of treating HCV is enormous. A 24-week treatment course is estimated at $10 200, but if either telaprevir or boceprevir is added, costs can go up to $70 000.

Hepatitis C specific diagnostic tests

Diagnostic tests can be divided into two general categories:

1. Serological assays: Detect antibodies to HCV and are used as screening tests for prior exposure to HCV.

2. Molecular assays: Detect, quantify, and characterise HCV RNA genomes within an infected patient.
   Categorised as:
   - Qualitative
   - Quantitative (quantitative PCR and branched DNA assay)
   - Genotyping

Molecular test is necessary to confirm the diagnosis.

Treatment of acute hepatitis C

Early treatment of acute HCV improves rates of viral clearance. Treatment should be started within 3 months after testing positive for HCV.

The current suggested treatment regimen consists of a combination of chemotherapy drugs for all types of hepatitis C:

- Interferon alpha (peginterferon alpha-2a) – 180 μg per week subcutaneously
- Ribavirin – 800 mg per day
- Boceprevir and telaprevir are recommended by the National Institute for Health and Clinical Excellence (NICE) as an option for the treatment of people with genotype 1.

Interferon alpha and ribavirin are on the South African national essential medicines list for the treatment of HCV; however, there are no guidelines available suggesting who is eligible for treatment.

Duration of treatment depends on the genotype. In patients with genotype 2 or 3, a 24-week course is effective, while a 48-week course is suggested for genotype 1. Genotype 5 responds similarly to type 2 and 3, and a 24-week course is recommended.

If no response (drop in viral load) is noted within 24 weeks of combination therapy, treatment should be stopped as no benefit has been proven with continued treatment.

Follow-up monitoring after completion of treatment should include serum aminotransferase levels and testing for HCV RNA at 6 months.

Interferon alpha and ribavirin are on the South African national essential medicines list for the treatment of HCV; however, there are no guidelines available suggesting who is eligible for treatment.
Prevention of hepatitis C

Hepatitis C vaccination

There is no reliable vaccine due to the unique characteristics of HCV, which include high replication rate and multiple mutation possibilities. Neutralising antibodies emerge too late to prevent chronic infection.16,22 Refer to Figure 4 for the suggested post-exposure protocol.

Should HCV positive surgeons refrain from operating? (surgeon risk to patient)

Current guidelines allow surgeons who are antibody-positive for HCV to continue performing procedures. If however it has been shown that they have transmitted HCV to a patient they are not allowed to continue operating.6,11,24

Currently in South Africa there are no guidelines advising infected surgeons on the reporting, assessment, and management of any incidents in which patients appear to have been exposed to a healthcare worker’s blood.23

There is controversy in identifying infected healthcare workers. At present there is no legislation on this subject.25

Risk to surgeon

Healthcare workers sustain 0.5–4.7 sharps-related injuries per year. The risk of virus transmission after percutaneous exposure is 1.8% (six times higher than the risk for HIV).11,23

Perception of surgeons regarding hepatitis C

In a questionnaire survey by the Royal College of Surgeons of England it was reported that 67% of orthopaedic surgeons do not routinely report sharps injuries or eye contamination.3

Medical insurance and post-exposure hepatitis C

The treatment cost of hepatitis C is expensive. Currently none of the insurance companies covers post-HCV exposure for healthcare workers.

Should HCV not be receiving the same insurance coverage as HIV?

Medical insurance and post-exposure hepatitis C

The treatment cost of hepatitis C is expensive. Currently none of the insurance companies covers post-HCV exposure for healthcare workers.

Should HCV not be receiving the same insurance coverage as HIV?
Conclusion

There is no cure for hepatitis C at the present, and no post-exposure prophylaxis is recommended. Immunoglobulins are not effective, interferon-alpha does not prevent transmission, antiviral agents have not been adequately assessed and there is no vaccine.\textsuperscript{26,25} Although surgeons fear transmission of HIV, it is hepatitis C which poses the greater risk.\textsuperscript{26}

When to initiate treatment:
• Two sequential anti-HCV positive tests
• HCV-RNA positive status fails to clear after 3 months

Suggested treatment:
• Interferon alpha
• Ribavirin

We would like to acknowledge the positive information and advice from Terry Grimmond from Hamilton New Zealand. The content of the article is the sole work of the authors. No benefits of any form have been or are to be received from a commercial party related directly or indirectly to the subject of the article.

References